DefinitionClick to collapse
Ampullary adenocarcinoma is defined as a malignant tumor originating from the ampulla of Vater, an anatomically complex region formed by three components: the ampulla itself, the intraduodenal portion of the bile duct, and the intraduodenal portion of the pancreatic duct [1, MS-2]. The ampulla of Vater is comprised of two mucosal tissue types: pancreatobiliary ductal mucosa and intestinal mucosa, which gives rise to two distinct histologic subtypes of ampullary cancer [MS-2]. Ampullary cancers must be distinguished from periampullary cancers, which may arise from locations encompassing the head of the pancreas, distal bile duct, duodenum, or ampulla of Vater [1, MS-2]. Distinction of periampullary tumors based on site of origin is particularly challenging, especially for large tumors that have invaded surrounding organs at presentation [16, 17, MS-2]. Each ampullary cancer subtype seems to resemble its periampullary counterpart in terms of biological behavior and prognosis, with the pancreatobiliary subtype demonstrating higher lymph node involvement and worse survival than the intestinal subtype [13, 18, 20, 24-26, MS-2]. Ampullary tumors generally have a more favorable outcome when compared to other periampullary malignancies [4, 6, 7, 10-15, MS-2]. In a single-institutional review of 2564 resected periampullary adenocarcinomas, the median survival for ampullary cancer was 47 months compared to 19, 23, and 54 months for pancreatic, biliary, and duodenal cancer, respectively [10, MS-2].
EpidemiologyClick to collapse
SubtypesClick to collapse
Intestinal type
Characterized by the presence of large tubules lined by tall columnar cells with elongated, pseudostratified, hyperchromatic nuclei resembling colonic-type adenocarcinoma. Immunophenotypic staining profile is typically positive for CK20, CDX2, and/or MUC2 with negative MUC1, or positive for CK20, CDX2, and MUC2 irrespective of MUC1 staining.
Pancreatobiliary type
Characterized by variably differentiated glands lined by non-stratified cuboidal or low columnar eosinophilic epithelium exhibiting round to oval, irregular, hypochromatic, or hyperchromatic nuclei with vesicular chromatin and irregular nuclear contours and a high nuclear to cytoplasmic ratio. Abundant desmoplastic stroma may be present. Immunophenotypic staining profile is positive for MUC1 and negative for CDX2 and MUC2 irrespective of CK20 staining.
Mixed type
A significant proportion of ampullary adenocarcinomas may be of mixed or ambiguous phenotype. These ambiguous cases should be classified as tubular adenocarcinoma with mixed features, with the predominant pattern noted in the pathology report for data collection purposes and future analysis.
Molecular PathogenesisClick to collapse
The genomic landscape of ampullary cancer shows important similarities and differences with other periampullary cancers. KRAS mutations occur in approximately 30%-40% of ampullary cancers, which is comparable to duodenal cancer but much lower than pancreatic cancer (~90%) [32-36, MS-4]. KRAS mutations appear more frequently in pancreatobiliary subtypes, though the distribution across histologic subtypes remains unclear due to small patient numbers [32, 33, MS-4]. Other somatic alterations reported include mutations in APC, TP53, CDKN2A, DPC4, ELF3, PIK3CA, and SMAD4, as well as HER2 amplifications and microsatellite instability (MSI) [37-41, MS-4]. Pathogenic germline mutations include BRCA1/2, ATM, RAD50, and MUTYH [39, 42, MS-4]. A genomic classification study of 3411 patients with periampullary cancers demonstrated high concordance between histologic subtypes and their respective genomic categories: the pancreatobiliary subtype has genomic signature similar to pancreatic adenocarcinoma (characterized by high KRAS mutations), while the intestinal subtype has genomic signature similar to colorectal adenocarcinoma (characterized by APC and PIK3CA mutations, higher TMB, and dMMR) [43, MS-4]. Somatic molecular profiling for metastatic disease should identify fusions (ALK, NRG1, NTRK, ROS1, FGFR2, and RET), mutations (BRAF, BRCA1/2, KRAS, and PALB2), amplifications (HER2), MSI, dMMR, or TMB using comprehensive genomic profiling via FDA-approved and/or validated NGS-based assays [h]. RNA sequencing assays are preferred for detecting RNA fusions because gene fusions are better detected by RNA-based NGS [h]. Testing on tumor tissue is preferred, though cell-free DNA testing can be considered if tumor tissue testing is not feasible [h]. HER2 overexpression occurs in 13% of ampullary cancers [MS-15]. BRAF V600E mutations have been reported with response rates of 37.9%-47% to dabrafenib/trametinib [158, 159].
Risk FactorsClick to collapse
Hereditary cancer syndromes
Genetic testing for inherited mutations is recommended for any patient with confirmed ampullary adenocarcinoma or positive family history of cancer. Pathogenic mutations include ATM, BRCA1, BRCA2, CDKN2A, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, and TP53 [b].
Familial adenomatous polyposis (FAP)
Ampullary adenomas can arise sporadically or in the setting of hereditary polyposis syndromes such as familial adenomatous polyposis [MS-5].
Pathogenic germline variants (BRCA1/2, ATM, RAD50, MUTYH)
Pathogenic germline mutations reported in ampullary cancer include BRCA1/2, ATM, RAD50, and MUTYH [39, 42, MS-4].
Clinical FeaturesClick to collapse
Typical Presentation
Ampullary adenocarcinoma often presents with symptoms of biliary obstruction, including jaundice, which is the most common initial sign due to the tumor's location at the ampulla of Vater, which obstructs the bile duct. Patients may also experience abdominal pain, typically in the epigastric or right upper quadrant, weight loss, and pruritus. Diagnosis is frequently made incidentally during endoscopic or radiographic evaluation for other gastrointestinal complaints or through workup of obstructive jaundice. The tumor's complex anatomical origin from the ampulla of Vater can make clinical distinction from other periampullary cancers challenging, particularly for large, invasive tumors.
Symptoms
Jaundice
Painless, progressive obstructive jaundice is the most common presenting symptom, resulting from bile duct obstruction by the tumor.
Abdominal Pain
Epigastric or right upper quadrant pain, which may be vague and intermittent.
Weight Loss
Unintentional weight loss, often associated with anorexia and early satiety.
Pruritus
Generalized itching due to bile salt deposition in the skin.
Nausea and Vomiting
May occur due to gastric outlet obstruction or duodenal involvement.
Signs
Jaundice
Yellowing of the sclera and skin.
Palpable Gallbladder (Courvoisier's Sign)
A palpable, non-tender gallbladder in the setting of painless jaundice.
Hepatomegaly
Enlargement of the liver, which may be due to biliary obstruction or metastatic disease.
Red FlagsClick to collapse
Obstructive jaundice (painless or with pruritus)
Unexplained weight loss greater than 5-10% of body weight
Epigastric or right upper quadrant pain persisting or worsening
Palpable gallbladder (Courvoisier's sign)
Cholangitis or fever associated with biliary obstruction
Signs of gastrointestinal bleeding (e.g., melena, hematemesis)
Palpable lymphadenopathy (e.g., Virchow's node)
InvestigationsClick to collapse
Diagnostic
Endoscopic Ultrasound (EUS) with biopsy
EUS is recommended as an adjunct to EGD to assess the depth of invasion, evaluate for pancreatic invasion (which mandates pancreatoduodenectomy), and obtain tissue for histologic diagnosis and subtyping.
Esophagogastroduodenoscopy (EGD) with a side-viewing endoscope
Provides direct visualization of the ampulla, allows for biopsy, and can assess for duodenal invasion or synchronous lesions.
Core biopsy of the primary or metastatic site
Core biopsy is recommended, if possible, to obtain adequate tissue for molecular profiling or other ancillary studies.
Colonoscopy
To exclude synchronous colonic polyps or neoplasms, especially in patients with hereditary syndromes like familial adenomatous polyposis (FAP).
Staging
Multi-detector computed tomography (MDCT) pancreatic protocol of abdomen and pelvis with contrast
Preferred imaging tool for dedicated pancreatic imaging. Provides assessment of tumor extent, vascular involvement, lymphadenopathy, and distant metastases.
Magnetic Resonance Imaging (MRI) with and without contrast
Most commonly used as a problem-solving tool, particularly for characterization of CT-indeterminate liver lesions or when contrast-enhanced CT cannot be obtained (e.g., severe iodinated contrast allergy).
Positron Emission Tomography/Computed Tomography (PET/CT) without iodinated IV contrast
The role remains unclear but can be used per institutional preference, especially if MRI cannot be performed (e.g., pacemaker-dependent patient). It is not a substitute for high-quality, contrast-enhanced CT.
Diagnostic staging laparoscopy
To rule out peritoneal or liver metastases not detected on preoperative imaging prior to surgery or chemoradiation.
Biomarkers
Carbohydrate antigen 19-9 (CA 19-9)
Tumor marker for ampullary adenocarcinoma, used for baseline measurement and monitoring response to therapy.
Carcinoembryonic antigen (CEA)
Tumor marker used in conjunction with CA 19-9 for baseline assessment and monitoring.
Tumor/somatic molecular profiling, preferably using a next-generation sequencing (NGS) assay
Recommended for patients with metastatic disease who are candidates for anti-cancer therapy to identify clinically actionable and/or emerging alterations.
Her2 overexpression via immunohistochemistry (IHC) ± fluorescence in situ hybridization (FISH)
To identify HER2 amplification, which is a targetable alteration in ampullary adenocarcinoma.
Microsatellite instability (MSI) or mismatch repair deficiency (dMMR)
To identify patients who may benefit from immune checkpoint inhibitor therapy.
Tumor mutational burden (TMB)
To identify patients with high TMB (≥10 mut/Mb) who may benefit from pembrolizumab.
Genetic testing for inherited mutations (e.g., ATM, BRCA1, BRCA2, CDKN2A, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53)
Recommended for any patient with confirmed ampullary adenocarcinoma or positive family history of cancer, using comprehensive gene panels for hereditary cancer syndromes.
StagingClick to collapse
AJCC Cancer Staging Manual, Eighth Edition (2017)
T Categories
| Stage | Description |
|---|---|
| TX | Primary tumor cannot be assessed. |
| T0 | No evidence of primary tumor. |
| Tis | Carcinoma in situ. |
| T1 | Tumor limited to ampulla of Vater or sphincter of Oddi or tumor invades beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa. |
| T1a | Tumor limited to ampulla of Vater or sphincter of Oddi. |
| T1b | Tumor invades beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa. |
| T2 | Tumor invades into the muscularis propria of the duodenum. |
| T3 | Tumor directly invades the pancreas (up to 0.5 cm) or tumor extends more than 0.5 cm into the pancreas, or extends into peripancreatic or periduodenal tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery. |
| T3a | Tumor directly invades pancreas (up to 0.5 cm). |
| T3b | Tumor extends more than 0.5 cm into the pancreas, or extends into peripancreatic tissue or periduodenal tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery. |
| T4 | Tumor involves the celiac axis, superior mesenteric artery, and/or common hepatic artery, irrespective of size. |
N Categories
| Stage | Description |
|---|---|
| NX | Regional lymph nodes cannot be assessed. |
| N0 | No regional lymph node metastasis. |
| N1 | Metastasis to one to three regional lymph nodes. |
| N2 | Metastasis to four or more regional lymph nodes. |
M Categories
| Stage | Description |
|---|---|
| M0 | No distant metastasis. |
| M1 | Distant metastasis. |
Stage Groupings
| Group | Criteria | Clinical Meaning | Five Yr Survival | Treatment Intent |
|---|---|---|---|---|
| Stage 0 | Tis, N0, M0 | Carcinoma in situ; excellent prognosis with surgical resection. | None | Curative |
| Stage IA | T1a, N0, M0 | Tumor limited to the ampulla of Vater or sphincter of Oddi; excellent prognosis with surgery. | None | Curative |
| Stage IB | T1b, T2, N0, M0 | Tumor invades beyond the sphincter of Oddi/duodenal submucosa or into the duodenal muscularis propria; good prognosis with surgery. | None | Curative |
| Stage IIA | T3a, N0, M0 | Tumor directly invades the pancreas (up to 0.5 cm); intermediate prognosis; surgery with consideration of adjuvant therapy. | None | Curative |
| Stage IIB | T3b, N0, M0 | Tumor extends more than 0.5 cm into the pancreas or into peripancreatic/periduodenal tissue; higher risk of recurrence; adjuvant therapy often recommended. | None | Curative |
| Stage IIIA | T1a, T1b, T2, T3a, T3b, N1, M0 | Regional lymph node metastasis (1-3 nodes); higher risk; adjuvant systemic therapy recommended. | None | Curative |
| Stage IIIB | T4, any N, M0; or any T, N2, M0 | Tumor involves major vascular structures (T4) or extensive lymph node metastasis (4 or more nodes); often considered locally advanced; multidisciplinary management including neoadjuvant therapy may be considered. | None | Curative or palliative, depending on resectability |
| Stage IV | Any T, any N, M1 | Distant metastatic disease; not curable with surgery; systemic therapy and palliative care. | None | Palliative |
Staging Pearls
- The ampulla of Vater is anatomically complex, comprising the ampulla, intraduodenal bile duct, and intraduodenal pancreatic duct. Tumors can arise from any component, making staging challenging.
- Adequate lymph node assessment is critical for staging. The panel consensus is to assess at least 12 lymph nodes in pancreatoduodenectomy specimens, though this may be more challenging after neoadjuvant therapy.
- The distinction between pancreatobiliary and intestinal histologic subtypes is important for prognosis and may influence therapy, but is not part of the TNM staging system.
- AJCC staging for ampullary adenocarcinoma is specific to this site and differs from staging for pancreatic or biliary cancers.
- Use of a standardized radiology reporting template (e.g., the Pancreatic Adenocarcinoma Radiology Reporting Template) is recommended to ensure complete assessment of vascular involvement and resectability.
Management PrinciplesClick to collapse
The management of ampullary adenocarcinoma is rooted in a multidisciplinary, stage-adapted approach that integrates local and systemic therapies with curative intent for localized disease and palliative intent for metastatic or recurrent disease. Treatment philosophy emphasizes early detection, accurate histologic subtyping (pancreatobiliary vs. intestinal), and molecular profiling to guide therapy selection. The ampulla of Vater is an anatomically complex region, and tumors here often present with early symptoms like jaundice, which may allow for earlier intervention compared to other periampullary cancers. Prognosis varies significantly based on TNM stage, differentiation grade, lymph node involvement, resection margin status, and histologic subtype, with the intestinal subtype generally having a more favorable prognosis than the pancreatobiliary subtype. A multimodal strategy is employed, with surgery (pancreatoduodenectomy) serving as the cornerstone for resectable disease, while systemic therapy is utilized in the neoadjuvant, adjuvant, and metastatic settings. Radiation therapy plays a complementary role in select scenarios to enhance local control. Supportive care and palliation are integral throughout the disease continuum to manage symptoms such as biliary obstruction, pain, and nutritional deficiencies, thereby maintaining quality of life [MS-2, MS-6, AMP-G].
Curative
Localized, resectable disease
Primary treatment is surgical resection (pancreatoduodenectomy). Neoadjuvant systemic therapy with or without chemoradiation may be considered for high-risk features, including equivocal imaging, markedly elevated tumor markers, large tumors, significant lymphadenopathy, or poor nutritional status. Adjuvant therapy is recommended postoperatively based on pathologic stage [AMP-4, AMP-5, MS-6, MS-9].
Adjuvant
Resected ampullary adenocarcinoma
Adjuvant systemic therapy is initiated within 12 weeks of surgery if medically fit. The regimen depends on histologic subtype and stage. For stage I, adjuvant chemotherapy or observation may be considered; for stages II and III, chemotherapy is recommended, often with subsequent chemoradiation for higher-risk features. Total duration of systemic therapy is typically 6 months [AMP-5, MS-9, MS-10].
Palliative
Metastatic or locally advanced unresectable disease
Systemic therapy is the mainstay, with regimens tailored to performance status and histologic subtype. Local therapies like radiation or surgery for oligometastatic disease may be considered for symptom control or in select cases with response to systemic therapy. Best supportive care is emphasized for poor performance status [AMP-6, MS-12].
Salvage
Disease progression after prior therapy
Options include clinical trials, alternative systemic regimens, targeted therapy based on molecular profiling, or palliative radiation for symptom relief. Treatment selection is guided by prior therapies, performance status, and molecular markers [AMP-7, MS-14].
Multidisciplinary consultation is essential for optimal management. The team should include expertise from diagnostic imaging, interventional endoscopy, medical oncology, radiation oncology, surgery, pathology, geriatric medicine, genetic counseling, and palliative care. Consultation with a registered dietitian is also recommended to address nutritional needs. Decisions about diagnostic management, resectability, and treatment planning should be made at high-volume centers with experience in periampullary cancers [AMP-3, MS-6].
Performance status (PS) is a critical determinant of treatment eligibility and intensity. Good PS is defined as ECOG 0–1 with good biliary drainage and adequate nutritional intake. Intermediate PS is defined as ECOG 2, where dose or schedule adjustments may be considered. Poor PS is defined as ECOG 3, for which palliative and best supportive care is preferred, though systemic or targeted therapy may be considered in selected cases [AMP-6, AMP-7, MS-12].
Management PathwaysClick to collapse
Branching: Endoscopic resectability, Presence of high-grade dysplasia, Margins after resection
Branching: Resectability, Performance status, Histologic subtype
Branching: Pathologic stage, Prior neoadjuvant therapy, Performance status
Branching: Performance status, Histologic subtype, Molecular profiling
Branching: Performance status, Prior therapy, Molecular profiling
Pretreatment EvaluationClick to collapse
Imaging
Laboratory
Endoscopic Evaluation
Pathology and Molecular Testing
Consultation
Staging Laparoscopy
SurgeryClick to collapse
Surgical resection is the primary curative treatment for localized ampullary adenocarcinoma. The goal is to achieve an R0 resection, which is associated with improved long-term survival. Surgery also provides tissue for pathologic staging and identification of prognostic factors [AMP-C, MS-6, MS-7].
Decisions about surgical management should involve multidisciplinary consultation at a high-volume center performing at least 15–20 pancreatic resections annually.
Careful intraoperative staging should rule out peritoneal, liver, and distant lymph node metastases; resection should only be done in the absence of distant disease.
Surgery should be efficient, minimizing blood loss, operative time, and cost.
Management of a soft pancreatic remnant should be anticipated.
Achievement of margin-negative resection requires meticulous perivascular dissection and potential vascular resection/reconstruction.
Frozen section analysis of pancreatic neck and bile duct margins is recommended to ensure at least 5 mm clearance.
Procedures
Pancreatoduodenectomy (Whipple technique)
Standard procedure for localized ampullary adenocarcinoma, especially for tumors with invasion beyond the sphincter of Oddi or into the pancreas.
Surgical ampullectomy
Selected cases with early-stage ampullary adenocarcinoma, but criteria are not well established; may be associated with higher recurrence rates.
Radiation TherapyClick to collapse
Radiation therapy (RT) plays a role in localized, locally advanced, recurrent, and palliative settings for ampullary adenocarcinoma. The goal is to sterilize vessel margins, enhance the likelihood of margin-negative resection, provide local control to prevent or delay progression or recurrence, and palliate symptoms such as pain, bleeding, or obstruction [AMP-F, MS-2, MS-12].
Principles
- Prior to RT initiation, staging should be optimally determined with CT abdomen with contrast and/or MRI with and without contrast.
- RT recommendations are based on four clinical scenarios: localized disease (neoadjuvant/adjuvant), locally advanced disease, recurrent disease, and palliative care.
- IMRT is preferred over 3D-CRT for conventional or hypofractionated RT, especially if dose escalation is considered.
- Motion management strategies (e.g., 4D-CT, respiratory gating) should be considered.
- Normal tissue dose constraints must be respected to minimize exposure to organs at risk (OARs) such as duodenum, stomach, liver, kidneys, spinal cord, and bowel.
Dose Frameworks
| Name | Total Dose | Dose Per Fraction | Fractions | Schedule | Indication |
|---|---|---|---|---|---|
| Conventional fractionation for chemoradiation | 45–54 Gy | 1.8–2.0 Gy | 25–30 | Daily fractions, typically 5 days per week | Localized/locally advanced disease, adjuvant setting, or palliative intent |
| Adjuvant RT after resection | 45–50.4 Gy | 1.8–2.0 Gy | 25–28 | Daily fractions | Adjuvant therapy for high-risk features (≥T3, positive nodes, positive margins, poor differentiation, perineural/perivascular invasion) |
Approaches
| Name | Dose Fractionation | Concurrent Chemotherapy | Indication | Key Trial | Toxicities |
|---|---|---|---|---|---|
| Neoadjuvant/adjuvant chemoradiation | 45–54 Gy in 1.8–2.0 Gy fractions | Capecitabine or fluorouracil with concurrent RT for all histologic types; gemcitabine with concurrent RT for pancreatobiliary type only. | Localized disease with high-risk features or adjuvant setting after resection. | Data extrapolated from pancreatic cancer trials; no ampullary-specific phase III data. | Acute gastrointestinal toxicities (nausea, diarrhea), fatigue; late toxicities depend on dose and volumes. |
| Definitive chemoradiation for locally advanced disease | 45–56 Gy in 1.8–2.2 Gy fractions | Capecitabine or fluorouracil. | Locally advanced unresectable disease without metastases. | Limited data; recommendations based on pancreatic cancer guidelines. | Similar to neoadjuvant/adjuvant setting. |
| Palliative radiation therapy | Various short courses (e.g., 8 Gy in 1 fraction, 30 Gy in 10 fractions) based on symptom burden and life expectancy. | May be used if not previously given as part of primary therapy. | Metastatic disease causing pain, obstruction, or bleeding; non-metastatic disease in patients unfit for definitive therapy. | No specific trials; individualized based on clinical scenario. | Minimal; focus on symptom control. |
| Stereotactic body radiation therapy (SBRT) | Variable (e.g., 33 Gy in 5 fractions); no definitive dose constraints. | Not typically concurrent. | Recurrent disease or oligometastatic disease; should be used at experienced centers or in clinical trials. Contraindicated if direct invasion of bowel or stomach on imaging. | Emerging data; not standard for ampullary cancer. | Risk of toxicity to adjacent organs; requires careful planning. |
Systemic TherapyClick to collapse
Systemic therapy is utilized across all stages of ampullary adenocarcinoma, including neoadjuvant, adjuvant, and metastatic settings. Treatment selection depends on histologic subtype (pancreatobiliary/mixed vs. intestinal), performance status, and molecular profiling. Most recommendations are extrapolated from pancreatic, biliary tract, and colorectal cancer guidelines due to limited ampullary-specific data [AMP-E, MS-2, MS-6].
Key Regimens
Treatment Response AssessmentClick to collapse
Title
Surveillance and Response Assessment for Ampullary Adenocarcinoma
Timing
After adjuvant therapy, surveillance is recommended every 3–6 months for 2 years, then every 6–12 months for up to 5 years as clinically indicated.
Response Logic
-
Serial imaging as indicated to assess disease response, especially in metastatic or recurrent settings.
-
Response assessment is based on clinical symptoms, imaging findings, and tumor markers (CEA, CA 19-9).
-
For patients on systemic therapy, imaging is typically performed every 2–3 cycles or as clinically indicated.
-
In metastatic disease, restaging after first-line therapy may guide consideration of local therapies for oligometastatic disease if response or stable disease is achieved.
Imaging Recommendations
-
History and physical (H&P) examination.
-
Chest CT and CT or MRI of abdomen and pelvis with contrast.
-
CEA and/or CA 19-9 measurements.
Biopsy Or Salvage Logic
-
Biopsy of new lesions may be considered to confirm progression or histologic transformation.
-
For local recurrence, salvage options include resection if feasible, radiation therapy, or systemic therapy.
-
Clinical trial enrollment is encouraged for progressive disease.
SurveillanceClick to collapse
Clinical Follow Up Schedule
- History and physical (H&P) examination every 3-6 months for 2 years, then every 6-12 months for up to 5 years as clinically indicated [AMP-5]
Imaging Strategy
- Chest CT and CT or MRI of abdomen and pelvis with contrast at each follow-up [AMP-5]
- Dedicated pancreatic protocol CT (preferred) or MRI with and without contrast for initial staging and follow-up [AMP-A]
- Consider MRI for indeterminate liver lesions as clinically indicated [AMP-3]
Laboratory Monitoring
- CEA and/or CA 19-9 at each follow-up [AMP-5]
Supportive Follow Up
- Nutritional evaluation as needed
- Pain management assessment
- Psychosocial support referral if needed
ComplicationsClick to collapse
Disease-Related
| Complication | Management |
|---|---|
| Biliary obstruction | Endoscopic biliary metal stent (preferred), percutaneous biliary drainage, open biliary-enteric bypass [AMP-G] |
| Gastric outlet/duodenal obstruction | For good PS: gastrojejunostomy ± G/J-tube or enteral stent; for poor PS: venting PEG tube or enteral stent [AMP-G] |
| Thromboembolic disease | Low-molecular-weight heparin preferred over warfarin; consider direct oral anticoagulants for patients without luminal tumors [AMP-G] |
| Bleeding from the primary tumor site | Therapeutic endoscopy, radiation therapy, angiography with embolization [AMP-G] |
| Pain | Early referral to pain specialist; opioids with or without neurolysis; EUS-guided celiac plexus neurolysis; palliative RT; SBRT; high-intensity focused ultrasound; intrathecal drug delivery [AMP-G] |
| Depression and malnutrition | Formal Palliative Medicine Service evaluation; nutritional evaluation with a registered dietitian; pancreatic enzyme replacement for exocrine pancreatic insufficiency [AMP-G] |
Supportive CareClick to collapse
Principles of Palliation and Supportive Care (AMP-G) aim to prevent and amelater suffering while ensuring optimal quality of life for patients with ampullary cancer.
Nutritional evaluation with a registered dietitian when available; pancreatic enzyme replacement for exocrine pancreatic insufficiency (starting dose at least 48,000 units lipase with meals, preferably 72,000) [AMP-G].
Not explicitly detailed in the provided text; standard antiemetic guidelines apply based on chemotherapy regimen used.
Not explicitly mentioned in the provided text.
Low-molecular-weight heparin preferred over warfarin for thromboembolic disease prophylaxis/treatment; consider direct oral anticoagulants for patients without luminal tumors [AMP-G].
Early referral to pain or palliative care specialist; opioids with or without neurolysis; EUS-guided celiac plexus neurolysis (fluoroscopic- or CT-guided if unavailable); celiac plexus radiation/radiosurgery; SBRT; high-intensity focused ultrasound; consider palliative radiation with or without chemotherapy if not already given; intrathecal drug delivery for severe tumor-associated abdominal pain unresponsive to optimal analgesic administration [AMP-G].
Formal Palliative Medicine Service evaluation when available; consider encouraging advanced care planning [AMP-G].
Not mentioned in the provided source text.
PrognosisClick to collapse
Ampullary adenocarcinoma is a rare malignancy, accounting for 0.2% of gastrointestinal malignancies and 6% of all periampullary cancers [2]. The 5-year overall survival (OS) for ampullary cancer is between 35% and 50%, but prognosis varies based on factors such as age, TNM classification, differentiation, grade, and treatment modality [3-9]. Ampullary tumors generally have a more favorable outcome compared to other periampullary malignancies, with a median survival of 47 months versus 19, 23, and 54 months for pancreatic, biliary, and duodenal cancer, respectively [10].
By Stage
| Stage | Five Yr Survival | Context |
|---|---|---|
| Stage I (AJCC 7th Edition) | 64% | Based on retrospective data [7]. |
| Stage II | 27% | Based on retrospective data [7]. |
| Stage III + IV | 17% | Based on retrospective data [7]. |
Prognostic Factors
- TNM stage, differentiation, grade, and treatment modality [3-9]
- Histologic subtype: pancreatobiliary subtype has higher lymph node involvement and worse survival than intestinal subtype [13,18,20,24-26]
- Lymph node metastasis: 5-year disease-specific survival is significantly higher for node-negative versus node-positive disease (59.4% vs. 28.4%; P<.001) [79]
- Number of positive lymph nodes: cumulative 5-year survival rates were 85% with 0 positive nodes, 63% with 1-3, and 0% with ≥4 (P<.0001) [89]
- Perineural invasion: median survival 18.7 vs. 51.9 months for cancers with vs. without (P=.001) [14]
- Tumor size, depth of invasion, lymphovascular invasion, resection margin status [4-6,8,12,66,76,80-83]
- Tumor markers CEA and CA 19-9, though prognostic utility is controversial [8,12,81,82,86]
Follow UpClick to collapse
Post Curative Treatment
After adjuvant therapy, surveillance is recommended every 3-6 months for 2 years, then every 6-12 months for up to 5 years or as clinically indicated [AMP-5].
Surveillance Rationale
To detect recurrence early, as recurrences can occur as early as <6 months and as late as 22.5 months after surgery [5,12,81,84,88,100].
Late Effects Screening
Not explicitly detailed in the provided text; long-term follow-up should consider potential delayed treatment effects such as pancreatic exocrine/endocrine insufficiency after surgery or radiation-induced toxicity.
Recurrence Patterns
Recurrence rates range between 28% and 55%, with distant recurrences making up ~80% in many studies [5,81,84,88,100]. The most common site of distant metastasis is the liver (38%–65% of distant recurrences); other sites include peritoneum, lung, and bones [5,81,84,88,100]. Pancreatic invasion and tumor size are predictive of locoregional recurrence, while lymph node involvement is the sole predictor for liver metastasis [5].
Key TrialsClick to collapse
| Acronym | Full Name | Year | N | Intervention | Comparator | Population | Primary Endpoint | Key Result | Secondary Outcomes | Practice Change | Journal |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ESPAC-3 | European Study Group for Pancreatic Cancer-3 Periampullary Cancer Randomized Trial | 2012 | 297 | Adjuvant chemotherapy with fluorouracil/leucovorin or gemcitabine | Observation | Patients with resected periampullary adenocarcinoma (including ampullary cancer) | Overall survival | No significant difference in OS between fluorouracil/leucovorin vs. gemcitabine (median OS 23.0 vs. 23.6 months). However, chemotherapy vs. observation improved OS (HR 0.75; 95% CI 0.57-0.98; P=.03) [5]. | Treatment-related serious adverse events were higher with fluorouracil/leucovorin than gemcitabine (49% vs. 30%; P=.002) [5]. | Established adjuvant chemotherapy (5-FU/leucovorin or gemcitabine) as standard of care for resected periampullary cancers. | JAMA |
| KEYNOTE-158 | Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer | 2020 | 233 | Pembrolizumab | None (single-arm) | Patients with advanced solid tumors including MSI-H/dMMR cancers (27 tumor types) | Objective response rate (ORR) | ORR 34.3%, median PFS 4.1 months, median OS 23.5 months [34,35]. | Grade 3-5 treatment-related adverse events 14.6% [34,35]. | Supported pembrolizumab for MSI-H/dMMR solid tumors regardless of histology. | Journal of Clinical Oncology |
| CheckMate 142 | Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer | 2018 | 119 | Nivolumab + ipilimumab | None (single-arm) | Previously treated MSI-H/dMMR metastatic colorectal cancer | Objective response rate | ORR 55%, 1-year PFS 71%, 1-year OS 85% [33,153]. | Grade 3-4 treatment-related adverse events 32% [33,153]. | Supported nivolumab plus ipilimumab for MSI-H/dMMR cancers. | Journal of Clinical Oncology |
| NAPOLI-1 | Nanoliposomal Irinotecan with Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer After Previous Gemcitabine-Based Therapy | 2016 | 417 | Nanoliposomal irinotecan + fluorouracil/folinic acid | Fluorouracil/folinic acid alone | Patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy | Overall survival | Improved OS (6.1 vs. 4.2 months; HR 0.75; 95% CI 0.61-0.92; P=.004) [162]. | Improved PFS (3.1 vs. 1.5 months; HR 0.57; 95% CI 0.45-0.73; P<.001) [162]. | Established nanoliposomal irinotecan + fluorouracil/folinic acid as a second-line option for metastatic pancreatic cancer. | The Lancet |
| PRODIGE 24/CCTG PA.6 | FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer | 2018 | 493 | Modified FOLFIRINOX | Gemcitabine | Patients with resected pancreatic cancer | Disease-free survival | mFOLFIRINOX significantly improved DFS (median 21.6 vs. 12.8 months; HR 0.58; 95% CI 0.46-0.74; P<.001) and OS (median 54.4 vs. 35.0 months; HR 0.64; 95% CI 0.48-0.86; P=.003) [137]. | Grade 3-4 adverse events higher with mFOLFIRINOX (75.9% vs. 52.9%) [137]. | Established mFOLFIRINOX as a standard adjuvant therapy for resected pancreatic cancer. | New England Journal of Medicine |
| DESTINY-PanTumor02 | Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors | 2024 | 187 | Trastuzumab deruxtecan | None (single-arm) | Patients with advanced solid tumors including pancreatic cancer | Objective response rate (ORR) | ORR 45.3% across all tumor types; in 25 patients with pancreatic cancer, ORR not separately reported [53,179]. | Median OS and PFS not separately reported for ampullary cancer [53,179]. | Supported trastuzumab deruxtecan for HER2-expressing solid tumors, including potential use in ampullary cancer. | Journal of Clinical Oncology |
| CONKO-001 | Adjuvant Chemotherapy with Gemcitabine and Long-Term Outcomes Among Patients with Resected Pancreatic Cancer | 2013 | 354 | Adjuvant gemcitabine | Observation | Patients with resected pancreatic cancer | Disease-free survival | Gemcitabine significantly improved DFS (median 13.4 vs. 6.9 months; HR 0.55; 95% CI 0.43-0.71; P<.001) and OS (median 22.8 vs. 20.2 months; HR 0.76; 95% CI 0.57-0.99; P=.047) [127]. | 5-year OS 20.7% vs. 15.4% [127]. | Established gemcitabine as standard adjuvant therapy for resected pancreatic cancer. | JAMA |
Clinical PearlsClick to collapse
- Pearl 1: Ampullary cancer is rare (0.2% of GI malignancies) but important due to pathologic variations and prognosis [2].
- Pearl 2: Histologic subtyping (pancreatobiliary vs. intestinal) is crucial for prognosis and may guide therapy selection; pancreatobiliary subtype has worse survival [13,18,20,24-26].
- Pearl 3: Genetic testing for inherited mutations (ATM, BRCA1/2, CDKN2A, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53) is recommended for all patients with ampullary adenocarcinoma [AMP-3 footnote b].
- Pearl 4: Neoadjuvant therapy can be considered in patients with high-risk features (equivocal imaging, markedly elevated CA 19-9/CEA, large tumors, etc.) [AMP-4].
- Pearl 5: Adjuvant chemotherapy (5-FU/leucovorin or gemcitabine) improves survival compared to observation (ESPAC-3 trial) [5].
- Pearl 6: Molecular profiling is recommended for metastatic disease to identify actionable alterations (fusions, mutations, amplifications, MSI, dMMR, TMB) [AMP-3 footnote h].
- Pearl 7: Endoscopic ampullectomy is an option for benign ampullary adenomas, but should be performed at high-volume centers; surgery is preferred for invasive cancer [AMP-2].
- Pearl 8: Chemoradiation may be used in the adjuvant setting for high-risk features (e.g., positive margins, node-positive disease) [AMP-5].